Cancer Research Cancer Research Funding Available  Genetics and Biology of Brain Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hamblin, M. R.
Right arrow Articles by Hasan, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hamblin, M. R.
Right arrow Articles by Hasan, T.
[Cancer Research 61, 7155-7162, October 1, 2001]
© 2001 American Association for Cancer Research


Experimental Therapeutics

Pegylation of a Chlorine6 Polymer Conjugate Increases Tumor Targeting of Photosensitizer1

Michael R. Hamblin, Jaimie L. Miller, Imran Rizvi, Bernhard Ortel, Edward V. Maytin2 and Tayyaba Hasan3

Wellman Laboratories of Photomedicine, Massachusetts General Hospital [M. R. H., J. L. M., I. R., B. O., T. H.], Boston, Massachusetts 02114, and Departments of Dermatology [M. R. H., B. O., T. H.] and Molecular Endocrinology [E. V. M.], Harvard Medical School, Boston, Massachusetts 02115

Photodynamic therapy is emerging as a viable modality for the treatment of many cancers. A limiting factor in its use against intracavity tumors such as disseminated ovarian cancer is insufficient selectivity of the photosensitizer for tumor compared with normal tissue. We report on an approach to improve tumor targeting by exploiting differences between cell types and by chemical modification of a photosensitizer conjugate. Attachment of polyethylene glycol (pegylation) to a polyacetylated conjugate between poly-l-lysine and chlorine6 increased the relative phototoxicity in vitro toward an ovarian cancer cell line (OVCAR-5) while reducing it toward a macrophage cell line (J774), compared with the nonpegylated conjugate. Surprisingly, the increased phototoxicity of the pegylated conjugate correlated with reduced oxygen consumption. Pegylation also reduced the tendency of the conjugate to aggregate and reduced the consumption of oxygen when the conjugates were illuminated in solution in serum containing medium, suggesting a switch in photochemical mechanism from type II (singlet oxygen) to type I (radicals or electron transfer). Pegylation led to more mitochondrial localization as shown by confocal fluorescence microscopy in OVCAR-5 cells, and, on illumination, produced a switch in cell death mechanism toward apoptosis not seen with J774 cells. Conjugates were injected i.p. into nude mice bearing i.p. OVCAR-5 tumors, and the pegylated conjugate gave higher amounts of photosensitizer in tumor and higher tumor:normal tissue ratios and increased the depth to which the chlorine6 penetrated into the peritoneal wall. Taken together, these results suggest that pegylation of a polymer-photosensitizer conjugate improves tumor-targeting and may increase the efficacy of photodynamic therapy for ovarian cancer.




This article has been cited by other articles:


Home page
JNMHome page
S. J. DeNardo, R. Liu, H. Albrecht, A. Natarajan, J. L. Sutcliffe, C. Anderson, L. Peng, R. Ferdani, S. R. Cherry, and K. S. Lam
111In-LLP2A-DOTA Polyethylene Glycol-Targeting {alpha}4{beta}1 Integrin: Comparative Pharmacokinetics for Imaging and Therapy of Lymphoid Malignancies
J. Nucl. Med., April 1, 2009; 50(4): 625 - 634.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
C. Falciani, M. Fabbrini, A. Pini, L. Lozzi, B. Lelli, S. Pileri, J. Brunetti, S. Bindi, S. Scali, and L. Bracci
Synthesis and biological activity of stable branched neurotensin peptides for tumor targeting
Mol. Cancer Ther., September 1, 2007; 6(9): 2441 - 2448.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
S. J. DeNardo, Z. Yao, K. S. Lam, A. Song, P. A. Burke, G. R. Mirick, K. R. Lamborn, R. T. O'Donnell, and G. L. DeNardo
Effect of Molecular Size of Pegylated Peptide on the Pharmacokinetics and Tumor Targeting in Lymphoma-Bearing Mice
Clin. Cancer Res., September 1, 2003; 9(10): 3854s - 3864s.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2001 by the American Association for Cancer Research.